Search - tctmd.com

Displaying 221 - 240 of 424

Sort: Relevancy | Date

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Opinion Editor's Corner

Q&A: Juan Granada Takes the Helm at the Cardiovascular Research Foundation

Shelley Wood

September 12, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Industry News

Medtronic Receives CE Mark for Attain Stability(TM) Quad MRI SureScan(TM) Active-Fixation Heart Lead

August 22, 2017

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

News Daily News

One in 10 TAVR Patients Treated Off-Label: TVT Registry

Michael O'Riordan

June 22, 2017

News Daily News

Almost Half of US Operators Do Under 50 PCIs Per Year: Does It Matter?

Shelley Wood

June 15, 2017

$Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It$

News Conference News SCAI 2017

Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It

L.A. McKeown

May 19, 2017

News Conference News SCAI 2017

#SoMe for #SciComm? Cardiologists See Value in Social Media, With Some Caveats

L.A. McKeown

May 10, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Shelley Wood

March 23, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

L.A. McKeown

March 21, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

Advertisement

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Q&A: Juan Granada Takes the Helm at the Cardiovascular Research Foundation

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Evolocumab Not Cost-Effective at Current List Price

Medtronic Receives CE Mark for Attain Stability(TM) Quad MRI SureScan(TM) Active-Fixation Heart Lead

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

One in 10 TAVR Patients Treated Off-Label: TVT Registry

Almost Half of US Operators Do Under 50 PCIs Per Year: Does It Matter?

Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It

#SoMe for #SciComm? Cardiologists See Value in Social Media, With Some Caveats

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Who Should Get a Statin? Guidelines Don’t Match Up

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

Live From Washington: ACC 2017, Day Three

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content